There was no difference in survival for t‐MN versus non‐t‐MN (Figure 3C and Supporting Information Figure S1D), suggesting that TP53 aberration is a confounding variable with regard to the association between t‐MN and increased risk for death (for patients with TP53‐aberrant MDS or AML). This evidence concerns the gene TP53 and myelodysplastic syndrome.